Moscow. May 17. INTERFAX.RU – An international team of scientists from the Menzies Health Institute of Queensland (MHIQ) at Griffith University (Australia) and from the City of Hope Medical Center (USA) has developed an experimental direct-acting antiviral therapy for the treatment of COVID-19, Griffith University reports.
“This next-generation antiviral approach used RNA gene suppression technology called miRNAs (small interfering RNAs) to directly attack the viral genome, which stops viral replication, and lipid nanoparticles developed at Griffith University and City of Hope to deliver miRNAs to the lungs. , a critical focus of infection, “the message says.
According to the researchers, treatment with virus-specific siRNA reduces viral load by 99.9%.
“Treatment with therapy in SARS-Cov-2 infected mice has improved survival and recovery rates.
It is noteworthy that not a single virus was found in the cured survivors in the lungs, “the message says.
One of the co-authors of the development, Professor Kevin Morris, notes that the drug is suitable for the treatment of all beta-coronaviruses, including new variants that may arise in the future, because it targets ultra-conserved regions of viral genomes.
At the same time, nanoparticles are stable at a temperature of 4 ° C for 12 months and at room temperature for more than one month, which means that this agent can be used in the absence of special storage conditions.
Previously, scientists reported about the possibility of creating a universal vaccine against several coronaviruses.